13F filings
Deep Track Capital
$6.1B to $6.9B. Includes price moves and buying or selling; not the fund's return.
Free on iOS and Android.
Sector mix of the disclosed holdings
by disclosed valueThe grey slice is mostly calls and puts (1.2% of the disclosed value), which get no sector because a put is a position against a company.
Largest holdings
50 largest of 67 positions| Holding | Type | Value | Shares | % of 13F value |
|---|---|---|---|---|
| GHGuardant Health | Shares | $509.1M | 3,393,312 | 7.4% |
| IMVTImmunovant | Shares | $359.9M | 9,341,151 | 5.2% |
| GPCRStructure Therapeutics | Shares | $254.4M | 4,740,072 | 3.7% |
| PCVXVaxcyte | Shares | $250.0M | 4,300,000 | 3.6% |
| ALNYAlnylam Pharmaceuticals | Shares | $248.3M | 825,000 | 3.6% |
| MANEVeradermics | Shares | $245.9M | 2,000,000 | 3.6% |
| TARSTarsus Pharmaceuticals | Shares | $230.8M | 3,666,768 | 3.4% |
| NUVLNuvalent | Shares | $220.2M | 1,783,322 | 3.2% |
| ALKSAlkermes | Shares | $209.6M | 4,000,000 | 3.1% |
| OCULOcular Therapeutix | Shares | $193.3M | 19,686,282 | 2.8% |
| BMRNBioMarin Pharmaceutical | Shares | $189.3M | 3,307,481 | 2.8% |
| NRIXNurix Therapeutics | Shares | $187.7M | 7,736,455 | 2.7% |
| ORKAOruka Therapeutics | Shares | $183.3M | 1,926,000 | 2.7% |
| ALMSAlumis | Shares | $178.6M | 6,348,558 | 2.6% |
| IONSIonis Pharmaceuticals | Shares | $174.4M | 2,200,000 | 2.5% |
| CMPSCOMPASS Pathways | Shares | $172.1M | 12,161,496 | 2.5% |
| VERAVera Therapeutics | Shares | $171.6M | 4,000,000 | 2.5% |
| AXSMAxsome Therapeutics | Shares | $171.3M | 700,000 | 2.5% |
| GMABGenmab A/S | Shares | $155.2M | 5,650,000 | 2.3% |
| MLTXMoonLake Immunotherapeutics | Shares | $136.3M | 6,999,025 | 2.0% |
| COAGHemab Therapeutics Holdings | Shares | $132.3M | 3,602,093 | 1.9% |
| TNGXTango Therapeutics | Shares | $131.3M | 4,200,000 | 1.9% |
| DFTXDefinium Therapeutics | Shares | $129.4M | 2,750,000 | 1.9% |
| GRALGRAIL | Shares | $125.3M | 1,834,944 | 1.8% |
| BCAXBicara Therapeutics | Shares | $121.7M | 4,100,000 | 1.8% |
| MAZEMaze Therapeutics | Shares | $111.4M | 3,732,569 | 1.6% |
| CLDXCelldex Therapeutics | Shares | $109.4M | 2,939,151 | 1.6% |
| LBRXLB Pharmaceuticals | Shares | $108.8M | 3,352,804 | 1.6% |
| MBXMBX Biosciences | Shares | $95.6M | 1,732,569 | 1.4% |
| GHRSGH Research | Shares | $89.6M | 3,333,334 | 1.3% |
| GMABGenmab A/S | Call | $82.4M | 3,000,000 | 1.2% |
| COGTCogent Biosciences | Shares | $77.4M | 2,000,000 | 1.1% |
| ATAIAtaibeckley | Shares | $76.0M | 14,417,442 | 1.1% |
| UTHRUnited Therapeutics | Shares | $67.0M | 123,616 | 1.0% |
| AVTXAvalo Therapeutics | Shares | $66.7M | 3,610,000 | 1.0% |
| VRDNViridian Therapeutics | Shares | $66.0M | 3,592,740 | 1.0% |
| CYTKCytokinetics | Shares | $59.6M | 700,000 | 0.9% |
| ALTAltimmune | Shares | $58.5M | 19,250,000 | 0.9% |
| PSNLPersonalis | Shares | $53.6M | 4,000,000 | 0.8% |
| ACRSAclaris Therapeutics | Shares | $49.4M | 9,345,000 | 0.7% |
| CRMDCorMedix | Shares | $49.3M | 6,274,076 | 0.7% |
| WGSGeneDx Holdings | Shares | $48.1M | 700,000 | 0.7% |
| HROWHarrow Health | Shares | $41.2M | 969,000 | 0.6% |
| CRVSCorvus Pharmaceuticals | Shares | $37.2M | 2,491,939 | 0.5% |
| SLDBSolid Biosciences | Shares | $35.6M | 3,565,062 | 0.5% |
| BEAMBeam Therapeutics | Shares | $34.3M | 1,000,000 | 0.5% |
| DYNDyne Therapeutics | Shares | $33.3M | 1,500,000 | 0.5% |
| IMMXImmix Biopharma | Shares | $28.6M | 2,775,000 | 0.4% |
| XFORX4 Pharmaceuticals | Shares | $27.5M | 5,878,757 | 0.4% |
| STTKShattuck Labs | Shares | $25.7M | 3,706,734 | 0.4% |
% of 13F value is the position's value against the whole disclosed 13F value, so the rows shown here do not sum to 100% unless every position is listed. Calls and puts are shown as filed: most filers give Value as the notional value of the shares underneath, not money invested, but some give the premium paid, and some count contracts rather than shares.
GetSignal pushes each new 13F to your phone as it is filed, with the positions that changed and the companies behind them. Free on iOS and Android.
What Deep Track Capital bought and sold in Q2 2026
15 largest moves| Holding | Move | Share change | Est. amount moved | Value after |
|---|---|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | Exited put | -100% | -$1.3B | $0 |
| ALNYAlnylam Pharmaceuticals | New | new | +$248.3M | $248.3M |
| MANEVeradermics | Added | +300.0% | +$184.4M | $245.9M |
| APLSApellis Pharmaceuticals | Exited | -100% | -$182.3M | $0 |
| COAGHemab Therapeutics Holdings | New | new | +$132.3M | $132.3M |
| CNTACentessa Pharmaceuticals | Exited | -100% | -$125.4M | $0 |
| BMRNBioMarin Pharmaceutical | Added | +187.6% | +$123.5M | $189.3M |
| AXSMAxsome Therapeutics | Trimmed | -36.4% | -$97.9M | $171.3M |
| GHRSGH Research | New | new | +$89.6M | $89.6M |
| IMVTImmunovant | Trimmed | -19.0% | -$84.2M | $359.9M |
| GMABGenmab A/S | New call | new | +$82.4M | $82.4M |
| UTHRUnited Therapeutics | New | new | +$67.0M | $67.0M |
| AVTXAvalo Therapeutics | New | new | +$66.7M | $66.7M |
| BBIOBridgeBio Pharma | Exited | -100% | -$62.5M | $0 |
| CLDXCelldex Therapeutics | Added | +128.9% | +$61.6M | $109.4M |
A change is this filing measured against the one before it. Est. amount moved is the shares added or sold, priced at the Jun 30, 2026 close. An estimate: a 13F gives no trade prices or dates. For a sold-out position, its value at the previous quarter end. A put gains when the stock falls; a call gains when it rises. Option values are as filed, which for most filers is the notional value of the shares underneath.
Questions
What does Deep Track Capital hold?
Deep Track Capital disclosed 67 positions worth $6.9B in the Q2 2026 13F filing. The largest is GH at 7.4% of the disclosed value. A 13F lists US-listed stock and options on it; short sales and cash are not in it.
What did Deep Track Capital buy and sell last quarter?
Comparing the Q2 2026 filing with the quarter before, the largest moves were selling out of a put on XBI, opening a position in ALNY, adding to MANE and selling out of APLS. Changes are measured against the previous filing, not against trades, because a 13F does not disclose trades.
How current is this?
This is the Q2 2026 filing, covering positions held on Jun 30, 2026 and filed with the SEC on Aug 14, 2026. A 13F is due 45 days after the quarter ends, so the most recent filing is always at least six weeks behind the market, and the manager may have changed the book since.
How to read a 13F
WHAT THE FILING COVERS
Positions are as disclosed to the SEC on Form 13F and are not investment advice. How this data is sourced, and what it cannot tell you, is on the methodology page. How the filing itself works is explained in our guide to Form 13F.
Checked for newer filings on Oct 26, 2026.